Asset

Treprostinil

United Therapeutics Corporation Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (6)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00067041phase2_3terminated2003-03-012003-12-01United TherapeuticsEffects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
NCT00004497phase3completed1998-10-01United TherapeuticsPhase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
NCT02847260phase4completed2012-04-012014-03-01United TherapeuticsSafety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
NCT00439946phase4terminated2007-02-012009-09-01United TherapeuticsSafety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
NCT00494533phase4terminated2005-03-012005-10-01United TherapeuticsStudy of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

FDA applications (4)

ApplicationTypeApplicant
NDA 021272NDAUNITED THERAPEUTICS CORP
NDA 022387NDAUNITED THERAPEUTICS CORP
NDA 208276NDAUNITED THERAPEUTICS CORP
NDA 214324NDAUNITED THERAPEUTICS CORP

Marketed products (18)

  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • REMODULIN
  • TYVASO
  • TYVASO DPI
  • TYVASO DPI
  • TYVASO DPI
  • TYVASO DPI
  • TYVASO DPI